Table 3.
Open in new tab

Absolute Blood eosinophil count trends in patients with Crohn’s disease on ustekinumab during induction (n = 191).

Mean eosinophil count, ×109/L (SD)Week 8 clinical responsea
Non-respondersRespondersP-value
Week 00.12 (0.1)0.18 (0.1).003
Week 20.16 (0.1)0.20 (0.2).047
Week 80.14 (0.1)0.14 (0.1).523
Week 8 absolute delta from baseline0.02 (0.1)−0.04 (0.1).024
Week 8 percent delta from baseline16.67% (66.6)−22.22% (69.6).004
Mean eosinophil count, ×109/L (SD)Week 8 clinical responsea
Non-respondersRespondersP-value
Week 00.12 (0.1)0.18 (0.1).003
Week 20.16 (0.1)0.20 (0.2).047
Week 80.14 (0.1)0.14 (0.1).523
Week 8 absolute delta from baseline0.02 (0.1)−0.04 (0.1).024
Week 8 percent delta from baseline16.67% (66.6)−22.22% (69.6).004

aReduction in CDAI of at least 100 points from baseline.

Table 3.
Open in new tab

Absolute Blood eosinophil count trends in patients with Crohn’s disease on ustekinumab during induction (n = 191).

Mean eosinophil count, ×109/L (SD)Week 8 clinical responsea
Non-respondersRespondersP-value
Week 00.12 (0.1)0.18 (0.1).003
Week 20.16 (0.1)0.20 (0.2).047
Week 80.14 (0.1)0.14 (0.1).523
Week 8 absolute delta from baseline0.02 (0.1)−0.04 (0.1).024
Week 8 percent delta from baseline16.67% (66.6)−22.22% (69.6).004
Mean eosinophil count, ×109/L (SD)Week 8 clinical responsea
Non-respondersRespondersP-value
Week 00.12 (0.1)0.18 (0.1).003
Week 20.16 (0.1)0.20 (0.2).047
Week 80.14 (0.1)0.14 (0.1).523
Week 8 absolute delta from baseline0.02 (0.1)−0.04 (0.1).024
Week 8 percent delta from baseline16.67% (66.6)−22.22% (69.6).004

aReduction in CDAI of at least 100 points from baseline.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close